Key Drivers
- Profitability Base
- Margin Compression
- Solid Liquidity
AIAI Summary
AMPH should now be viewed as a higher-risk turnaround rather than a steady cash generator: the balance sheet and cash flow still provide cushion, but the sharp margin compression and securities-law investigation mean the stock only deserves rerating if management can prove the proprietary/biosimilar pivot restores profitability.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Base
- •Margin Compression
- •Solid Liquidity
AMPH shows solid full-year profitability and liquidity, but recent quarter margins and interest coverage weakened materially, so the stock hinges on whether annual earnings strength can be sustained.
Price Behavior
Key Price Behavior Insights:
- •Rebound stalled
- •Support holding
- •Short-term fade
AMPH is modestly higher over the last month, but the late-June rebound stalled below $21.8 and the near-term outlook stays fragile unless $19.50 support holds.
Sharp jump from $18.33 to $21.78 in late
Sentiment & News
Key News Insights:
- •Business pivot
- •Securities probe
- •Weak sentiment
Amphastar is pivoting toward proprietary drugs and biosimilars, but ongoing securities-law scrutiny and a Strong Sell rating point to mounting market caution.
This news is likely a near-term overhang on AMPH as strategic progress is offset by legal risk and deteriorating investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings